Skip to Content

Bivigam Approval History

  • FDA approved: Yes (First approved December 21st, 2012)
  • Brand name: Bivigam
  • Generic name: immune globulin intravenous
  • Dosage form: Infusion
  • Company: Biotest Pharmaceuticals Corporation
  • Treatment for: Primary Immunodeficiency Syndrome

Bivigam is an immune globulin intravenous (human) indicated for the treatment of primary humoral immunodeficiency.

Development History and FDA Approval Process for Bivigam

Dec 21, 2012Approval FDA Approves Biotest's Bivigam, an Intravenous Immune Globulin (Human), 10% Liquid

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.